Phase III, Open-Label, Multicenter International Study to Evaluate the Efficacy and Safety of an Octreotide Implant vs. Sandostatin LAR Depot in Patients With Acromegaly

Inclusion Criteria:

- Male and female patients with acromegaly

- Confirmed diagnosis of a growth hormone-secreting tumor

- Received a stable dose of monthly octreotide depot injections for a minimum of 3
consecutive months immediately prior to screening

- Must show a response to octreotide treatment with documented laboratory results at
the screening visits defined as follows: IGF-1 < 20% above the upper limit of normal
age and sex-adjusted levels and GH ≤ 2.5 ng/mL

Exclusion Criteria:

- Patients with pituitary surgery less than 3 months prior to screening

- Uncontrolled diabetes defined as having a fasting glucose > 150 mg/dl and HbA1c >= 9%

- Symptomatic cholelithiasis

- Received pegvisomant, Lanreotide, or a dopamine agonist within 3 months of screening,
or at any time during the trial

- Received radiotherapy for pituitary tumor or any radiotherapy above the neck at any
time before Screening